OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU™ [Immune Globulin ...

- Hizentra ® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S. - Hizentra is the first and only subcutaneous immune globulin (SCIg) treatment approved for Chronic ...

“The availability of the 10g prefilled syringe is CSL Behring’s latest development in helping the rare disease community effectively manage PI and CIDP, as some patients may require treatment at a ...

The prescribed dosage for Hizentra (immune globulin subcutaneous [human]) may vary depending on an individual’s treatment plan. Other factors, including your specific diagnosis, body weight, and ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on Friday that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA (Immune Globulin Infusion 10% with Recombinant Human ...

It was a decade and four companies ago that HyQvia was first approved by the FDA for primary immunodeficiency (PI). Ten years later, Takeda’s subcutaneous immune globulin treatment has scored its ...

Please provide your email address to receive an email when new articles are posted on . Immunoglobulin replacement therapy triggered severe neuropathy. A 4,200 U dose ...

Increasing adoption of XEMBIFY is part of Grifols’ broader Ig business strategy focused on treating immunodeficiencies, which represent more than half of the total Ig market and whose growth is ...

(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] ...

In patients with inborn errors of immunity who are prone to viral infections, immunoglobulin replacement therapy (IRT) administered via the conventional subcutaneous route showed lower viral infection ...